Metformin Alleviates Cognitive Impairment in Chronic-Phase Epileptic Rats by Modulating the TLR4/MyD88/NF-κB Pathway...

Area of Science:

• Neuroscience
• Microbiology
• Pharmacology

Background:

• Epilepsy (EP) is a neurological disorder characterized by seizures and cognitive impairment.
• Current treatments for epilepsy-associated cognitive impairment are limited due to unknown pathogenic pathways.
• Metformin, an antidiabetic drug, shows potential in epilepsy models, possibly by influencing gut microbiota and cognition.

Purpose of the Study:

• To investigate the protective effect of metformin on cognitive function in chronic epilepsy in rats.
• To determine if metformin's effects on cognition are mediated by alterations in the gut microbiota.
• To elucidate the underlying mechanisms, including inflammatory pathways.

Main Methods:

• Utilized a pilocarpine-induced chronic epilepsy rat model.
• Performed multi-omics analysis, including 16S rDNA sequencing and 4D label-free proteomics.
• Assessed spatial learning, memory, hippocampal neuronal damage, synaptic plasticity, gut microbiota composition, and inflammatory markers (TLR4/MyD88/NF-κB pathway).

Main Results:

• Metformin treatment improved spatial learning and memory in epileptic rats.
• It reduced hippocampal neuronal damage and enhanced synaptic plasticity.
• Metformin reversed epilepsy-associated gut microbiota alterations, increased beneficial bacteria, and reduced harmful ones, promoting gut homeostasis.
• Metformin inhibited the TLR4/MyD88/NF-κB pathway, alleviating systemic inflammation.

Conclusions:

• Metformin ameliorates cognitive impairment in chronic epilepsy.
• The therapeutic effects are likely facilitated by gut microbiota modulation.
• Potential mechanisms involve suppressing the TLR4/MyD88/NF-κB signaling pathway and reducing inflammation.